Chemistry:Lys-MDA
From HandWiki
Short description: Chemical compound
 | |
| Clinical data | |
|---|---|
| ATC code |
|
| Identifiers | |
| |
| CAS Number | |
| Chemical and physical data | |
| Formula | C16H25N3O3 |
| Molar mass | 307.394 g·mol−1 |
| 3D model (JSmol) | |
| |
Lys-MDA (Lysine-MDA, N-(L-lysinamidyl)-3,4-methylenedioxyamphetamine) is a substituted amphetamine derivative with empathogenic effects, which acts as a prodrug for MDA with a slower onset of effects and longer duration of action. Lys-MDA, along with the related derivative Lys-MDMA, are in early stage human clinical trials as potential treatments for treatment-resistant depression and post-traumatic stress disorder.Currently new MDMA prodrugs are in the development phase at MiHKAL GmbH in Switzerland.[1][2][3][4]
Lys-MDMA [1]
See also
- Lisdexamphetamine
- N-t-BOC-MDMA
References
- ↑ "MindMed announces Phase 1 study of MDMA-like substances.". Drug Discovery and Development. 21 September 2022. https://www.drugdiscoverytrends.com/mindmed-announces-phase-1-study-of-mdma-like-substances/.
- ↑ "MindMed Collaborators Dose First Patient in Phase 1 Investigator-Initiated Trial of MDMA-Like Substances.". Biospace.com. 20 September 2022. https://www.biospace.com/article/releases/mindmed-collaborators-dose-first-patient-in-phase-1-investigator-initiated-trial-of-mdma-like-substances/.
- ↑ Grill M, "Novel Safrylamine derivatives having prodrug properties.", WO patent 2022/053696, published 17 March 2022, assigned to Compass Pathfinder Limited.
- ↑ Clark S, Duncton MA, "Methylenedioxymethamphetamine and Related Psychedelics and Uses Thereof", WO patent 2023/283373, published 12 January 2023, assigned to Terran Biosciences Inc.
 |  |
